Development and use of alefacept to treat psoriasis
Open Access
- 31 August 2003
- journal article
- review article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 49 (2) , 87-97
- https://doi.org/10.1016/mjd.2003.552
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasisJournal of the American Academy of Dermatology, 2002
- Treatment of psoriasis. Part 2. Systemic therapiesJournal of the American Academy of Dermatology, 2001
- Treatment of psoriasis. Part 1. Topical therapy and phototherapyJournal of the American Academy of Dermatology, 2001
- Treatment of Chronic Plaque Psoriasis by Selective Targeting of Memory Effector T LymphocytesNew England Journal of Medicine, 2001
- Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotypeArchives of Dermatological Research, 2000
- Two considerations for patients with psoriasis and their clinicians:: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?Journal of the American Academy of Dermatology, 2000
- The pathogenesis of psoriasis: immunological facts and speculationsPublished by Elsevier ,1999
- Low affinity binding of an LFA-3/IgG1 fusion protein to CD2+T cells is independent of cell activationCell Adhesion and Communication, 1999
- Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses.The Journal of Experimental Medicine, 1993
- Severe Psoriasis – Oral Therapy with a New RetinoidDermatology, 1978